GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enorama Pharma AB (OSTO:ERMA) » Definitions » Equity-to-Asset

Enorama Pharma AB (OSTO:ERMA) Equity-to-Asset : 0.57 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Enorama Pharma AB Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Enorama Pharma AB's Total Stockholders Equity for the quarter that ended in Dec. 2023 was kr19.54 Mil. Enorama Pharma AB's Total Assets for the quarter that ended in Dec. 2023 was kr34.39 Mil. Therefore, Enorama Pharma AB's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.57.

The historical rank and industry rank for Enorama Pharma AB's Equity-to-Asset or its related term are showing as below:

OSTO:ERMA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.04   Med: 0.52   Max: 0.72
Current: 0.57

During the past 10 years, the highest Equity to Asset Ratio of Enorama Pharma AB was 0.72. The lowest was 0.04. And the median was 0.52.

OSTO:ERMA's Equity-to-Asset is ranked worse than
51.19% of 1088 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs OSTO:ERMA: 0.57

Enorama Pharma AB Equity-to-Asset Historical Data

The historical data trend for Enorama Pharma AB's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enorama Pharma AB Equity-to-Asset Chart

Enorama Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.04 0.42 0.65 0.57

Enorama Pharma AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.60 0.38 0.53 0.57

Competitive Comparison of Enorama Pharma AB's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enorama Pharma AB's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Enorama Pharma AB's Equity-to-Asset falls into.



Enorama Pharma AB Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Enorama Pharma AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=19.538/34.385
=0.57

Enorama Pharma AB's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=19.538/34.385
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enorama Pharma AB  (OSTO:ERMA) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Enorama Pharma AB Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Enorama Pharma AB's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Enorama Pharma AB (OSTO:ERMA) Business Description

Traded in Other Exchanges
N/A
Address
Sodergatan 3, Malmo, SWE, SE-211 34
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.

Enorama Pharma AB (OSTO:ERMA) Headlines

No Headlines